How a personalized cancer vaccine is designed
Follow a tumor alteration through discovery, target selection, manufacture and testing of the immune response. A vaccine is a defined intervention. A list of mutations is only one input.
The big ideas
- A neoantigen comes from altered sequence, but most candidate sequences still face expression, processing and display gates.
- Human leukocyte antigen (HLA) displays fragments; a T-cell receptor (TCR) recognizes the fragment together with its holder.
- Priming, tumor recognition and clinical benefit require different evidence.
- An mRNA construct and its delivery formulation are separate design choices. A clean batch can still encode weak targets.
- Immune expansion is not proof of recurrence prevention. Dose, route and schedule belong to the specific protocol.
The map
Follow the numbered links below through the same sequence. Each gate asks a new question.
Lessons
Times are suggested reading budgets, not measured completion times. The final evidence guide is a shared capstone.
| Step | Lesson | Question | Minutes | Learning aid |
|---|---|---|---|---|
| 1 | Why vaccination can help | How does a pre-existing receptor become a larger response? | 8 | Priming-versus-killing example |
| 2 | Read tumor and normal data | Which alterations are credible candidate sources? | 12 | Evidence ledger |
| 3 | Match HLA and presentation | What does an HLA type constrain? | 8 | Display-versus-recognition map |
| 4 | Read a target design board | Which gates are measured, predicted or missing? | 12 | Candidate comparison |
| 5 | Measure displayed peptides | What does detection or non-detection establish? | 8 | Assay interpretation table |
| 6 | Write the message | What changes when targets become one construct? | 10 | Linker-change scenario |
| 7 | Make the product | How do sequence, formulation and release differ? | 10 | Controlled handoff |
| 8 | Dose and measure response | What shows immunogenicity, safety or benefit? | 12 | Assay-to-claim exercise |
| 9 | Read cancer evidence | What comparison can establish clinical benefit? | 10 | Endpoint and denominator check |
Concepts you will use
Foundations: DNA → RNA → protein, innate and adaptive immunity, the immune-cell roster.
Recognition: neoantigen, antigen processing, beta-2 microglobulin (B2M), cross-presentation, T-cell priming and T-cell states.
Product and failure modes: lipid nanoparticles (LNPs), immune escape and the construct page above. Return to these explanations whenever a lesson uses an unfamiliar term.
Applied to Diana
The molecular profile, vaccine readiness, vaccine evidence and the care plan own current findings, decisions and logistics. This guide supplies the questions for reading those owners.
What is still uncertain
Target-ranking methods differ in what they predict and how they were validated. A measured immune response may fail to control a tumor. Small studies cannot isolate vaccine benefit from standard care, selection and other treatments. Formulation and combination results must retain their original cancer population and protocol.
Sources and scope
Source check: October 8, 2026; expert and learner review pending. Individual lessons supply their sources. TNBC-MERIT and the pancreatic-cancer RNA-lipoplex study are specific clinical examples, not universal product specifications.